非小细胞肺癌患者血清血管内皮生长因子C的水平及临床意义

Expression of VEGF-C in the Serum of NSCLC Patients and Its Clinicopathologic Significance

目的:本研究探讨非小细胞肺癌患者(NSCLC)血清中血管内皮生长因子C(VEGF-C)的表达水平及其与患者临床病理特征之间的关系。方法:收集20例体检正常健康者、30例肺炎患者及60例NSCLC患者血清,用ELISA方法检测血清VEGF-C表达水平。结果:NSCLC、肺炎患者和正常健康者血清VEGF-C表达水平分别为124.8±95.4、78.1±55.2和63.8±46.2pg/ml,NSCLC患者表达水平与肺炎患者和正常健康者相比,差异具有显著统计学差异(P<0.05),后二者之间无显著统计学差异(P>0.05);NSCLC患者血清中VEGF-C表达水平与TNM分期及淋巴结转移具有显著相关性,与其它因素无明显相关性;NSCLC患者血清VEGF-C与患者存活时间密切相关,生存时间大于6个月患者35例,其血清VEGF-C平均表达水平为97.5±85.3pg/ml,而生存时间小于6个月的25例患者平均表达水平为161.4±145.2pg/ml,二者比较具有显著统计学差异(P<0.05)。结论:NSCLC患者血清VEGF-C的表达较正常人群及肺炎患者明显升高,并与NSCLC患者病情进展密切相关,可作为一种辅助诊断及有价值的预后参考指标。

Objective： To investigate the relationship between the serum vascular endothelial growth factor-C （VEGF-C） level and the clinicopathological features in patients with non-small cell lung cancer （NSCLC）. Methods： Serum level of VEGF-C in 20 healthy normal controls, 30 cases of pneumonia, and 60 cases of NSCLC were detected by ELISA. The relationship between VEGF-C expression and the clinical features was analyzed. Results： Serum VEGF-C in the NSCLC patients was significantly higher than in the healthy controls （P〈0.01） and patients with pneumonia （P〈0.05）. NSCLC patients with lymph node metastasis had a higher VEGF-C level than those without lymph node metastasis （P〈0.05）. Stage Ⅲ and stage Ⅳ NSCLC patients had a higher VEGF-C level than stage Ⅰ and stage Ⅱ NSCLC patients （P〈0.01）. Serum VEGF-C level had a negative correlation with the survival time of NSCLC patients （P〈0.05）. Conclusion： Serum VEGF-C level in NSCLC patients is correlated with disease progression and survival time. Serum VEGF-C level can therefore serve as a prognostic marker of NSCLC.